Skip to content

Author

Xu Wang

We have 2 of 21 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

SGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis

A Bayesian network meta-analysis comparing SGLT2 inhibitors, semaglutide, and finerenone—the three therapies with contemporary phase 3 cardiorenal evidence—to define their comparative efficacy and safety hierarchy in type 2 diabetes with chronic kidney disease supports a four-pillar framework.

Zong-Ze He, Xu Wang, Li Zhang et al. · 0 citations
Aug 2026

Formononetin attenuates early diabetic retinal and renal microvascular injury associated with EGR1/VEGF-related endothelial responses.

FMN attenuated early diabetes-associated retinal and renal injury and was linked to EGR1/VEGF-related endothelial responses, which support EGR1 involvement but do not establish it as the sole target or mediator of FMN.

Xiao-Qiang Gao, Xiao-Niao Chen, Luying Qiao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.